<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: Therapeutic cerebral <z:mpath ids='MPATH_177'>angiogenesis</z:mpath>, utilizing angiogenic factors to enhance collateral vessel formation within the central <z:mp ids='MP_0008912'>nervous</z:mp> system, is a potential method for cerebral revascularization </plain></SENT>
<SENT sid="1" pm="."><plain>A prior dose-response study determined that intracerebroventricular infusion of vascular endothelial growth factor (VEGF) increases vascular density with minimal associated <z:hpo ids='HP_0002181'>brain edema</z:hpo> at a concentration of 5 microg/ml </plain></SENT>
<SENT sid="2" pm="."><plain>The purpose of this study was to assess effects of intracerebroventricular infusion of VEGF (5 microg/ml) on cerebral blood flow, <z:mpath ids='MPATH_124'>infarct</z:mpath> volume, and <z:hpo ids='HP_0002181'>brain edema</z:hpo> after <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>METHODS: Recombinant human VEGF(165) was infused into the right lateral ventricle of rats with an osmotic minipump at a rate of 1 microl/hr for 7 days </plain></SENT>
<SENT sid="4" pm="."><plain>Control animals received vehicle only </plain></SENT>
<SENT sid="5" pm="."><plain><z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">Ischemia</z:e> was produced by transient (2 hours) middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> (MCAO) </plain></SENT>
<SENT sid="6" pm="."><plain>After MCAO, cerebral blood flow was determined with the indicator fractionation technique: <z:mpath ids='MPATH_124'>infarct</z:mpath> volume was assessed with 2,3,5-triphenlytetrazolium <z:chebi fb="76" ids="17996">chloride</z:chebi> staining, and <z:hpo ids='HP_0002181'>brain edema</z:hpo> was determined by measuring brain water content </plain></SENT>
<SENT sid="7" pm="."><plain>FINDINGS: Cerebral blood flow was not significantly different in animals treated with VEGF compared to controls </plain></SENT>
<SENT sid="8" pm="."><plain>There was a significant reduction in total <z:mpath ids='MPATH_124'>infarct</z:mpath> volume after temporary MCAO in VEGF-treated animals compared to controls (163+/-37 mm(3) vs. 309+/-54 mm(3), P&lt;0.05) </plain></SENT>
<SENT sid="9" pm="."><plain>Brain water content after transient MCAO was also significantly reduced in VEGF-treated animals compared to controls (80.9+/-0.7% vs. 83.3+/-0.6%, P&lt;0.05) </plain></SENT>
<SENT sid="10" pm="."><plain>INTERPRETATION: Intracerebroventricular infusion of VEGF(165) (5 microg/ml) decreases <z:mpath ids='MPATH_124'>infarct</z:mpath> volume and <z:hpo ids='HP_0002181'>brain edema</z:hpo> after temporary MCAO without a significant increase in cerebral blood flow </plain></SENT>
<SENT sid="11" pm="."><plain>These results indicate that VEGF may have a direct neuroprotective effect in <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo> </plain></SENT>
</text></document>